Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karin Hartmann

Showing results (101-110 of 189) with videos related to

Pageof 19
Sort By:
Immunity|June 28, 2011
Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptensAnne Dudeck, Jan Dudeck, Julia Scholten, et al.
International Journal of Molecular Sciences|December 2, 2020
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized MedicinePeter Valent, Cem Akin, Boguslaw Nedoszytko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 10, 2023
Fatal and Near-Fatal Anaphylaxis: Data From the European Anaphylaxis Registry and National Health StatisticsVeronika Höfer, Sabine Dölle-Bierke, Wojciech Francuzik, et al.
European Journal of Dermatology : EJD|March 9, 2011
Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutationsWibke von Bartenwerffer, Cristina Has, Meral J Arin, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
Leukemia & Lymphoma|September 20, 2012
Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophilsAnja Förster, Franco H Falcone, Bernhard F Gibbs, et al.
Blood|August 7, 2010
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD)Peter Valent, Michel Arock, Cem Akin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell LymphomaSebastian Theurich, Max Schlaak, Harold Steguweit, et al.
Oncotarget|January 22, 2015
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemiaSabine Cerny-Reiterer, Anja Rabenhorst, Gabriele Stefanzl, et al.
Allergy|June 13, 2025
A Growing Concern for Cashew and an Unexpected Risk From Almonds: Data From the Anaphylaxis RegistryVeronika Höfer, Sabine Dölle-Bierke, Dominique Sabouraud-Leclerc, et al.
Pageof 19

Showing results (101-110 of 189) with videos related to

Sort By:
Pageof 19
Immunity|June 28, 2011
Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptensAnne Dudeck, Jan Dudeck, Julia Scholten, et al.
International Journal of Molecular Sciences|December 2, 2020
Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized MedicinePeter Valent, Cem Akin, Boguslaw Nedoszytko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|October 10, 2023
Fatal and Near-Fatal Anaphylaxis: Data From the European Anaphylaxis Registry and National Health StatisticsVeronika Höfer, Sabine Dölle-Bierke, Wojciech Francuzik, et al.
European Journal of Dermatology : EJD|March 9, 2011
Mild recessive dystrophic epidermolysis bullosa associated with two compound heterozygous COL7A1 mutationsWibke von Bartenwerffer, Cristina Has, Meral J Arin, et al.
International Archives of Allergy and Immunology|July 1, 2019
Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation SyndromePeter Valent, Patrizia Bonadonna, Karin Hartmann, et al.
Leukemia & Lymphoma|September 20, 2012
Anti-Fas/CD95 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) differentially regulate apoptosis in normal and neoplastic human basophilsAnja Förster, Franco H Falcone, Bernhard F Gibbs, et al.
Blood|August 7, 2010
The classification of systemic mastocytosis should include mast cell leukemia (MCL) and systemic mastocytosis with a clonal hematologic non-mast cell lineage disease (SM-AHNMD)Peter Valent, Michel Arock, Cem Akin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2014
Targeting Tumor-Infiltrating B Cells in Cutaneous T-Cell LymphomaSebastian Theurich, Max Schlaak, Harold Steguweit, et al.
Oncotarget|January 22, 2015
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemiaSabine Cerny-Reiterer, Anja Rabenhorst, Gabriele Stefanzl, et al.
Allergy|June 13, 2025
A Growing Concern for Cashew and an Unexpected Risk From Almonds: Data From the Anaphylaxis RegistryVeronika Höfer, Sabine Dölle-Bierke, Dominique Sabouraud-Leclerc, et al.
Pageof 19